What goes into real lung cancer treatment decisions? 🫁Watch experts break down 2 real cases: • Stage III NSCLC • EGFR therapy before & after surgery. Led by @DDoroshow + panel🎥 Get a “fly on the wall” view of expert thinking

🔗 www.youtube.com/playlist?lis...
#LungCancer #NSCLC #Oncology

Predicting Stereotactic Body Radiation Therapy Response Using an AI-Based Tumor Vessel Biomarker
@tcrtcancer.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#lungcancer #NSCLC #cancerprognostic #medicalimaging #oncology #openaccess

Ivonescimab Improves Quality of Life in First-Line NSCLC Patients without Chemotherapy The HARMONi-2 study reveals that Ivonescimab significantly enhances health-related quality of life for NSCLC patients without chemotherapy, outperforming Pembrolizumab.

Ivonescimab Improves Quality of Life in First-Line NSCLC Patients without Chemotherapy #China #Hong_Kong #Akeso #Ivonescimab #NSCLC

Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration The decision regarding resectability in stage III non-small-cell lung cancer (NSCLC) is complex. To improve consistency in eligibility criteria in clinical trials, the European Organisation for Resear...

🏥 New: Position Paper on #NSCLC

📰 Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration

🔗 www.thelancet.com/journals/lan...

🆕Our April issue is live!

📊Articles: #NSCLC, #bladdercancer, #melanoma, #prostatecancer, #breastcancer

📰Reviews: A PSOGI–ESGO–ISSPP Lyon consensus & OPTIMISE-AR recommendations for visualising PROs

Cover: Spaceflight as a cancer research catalyst

www.thelancet.com/issue/S1470-...

EMPOWER-Lung3 Analysis Reveals Differential Outcomes With Cemiplimab/Chemo in Genomic Subsets of NSCLC | OncLive Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

🫁Varying outcomes were observed following treatment with cemiplimab-rwlc plus chemotherapy in molecularly defined subsets of patients with nonsquamous NSCLC @myesmo.bsky.social #lscm #NSCLC #oncology #ELCC26
www.onclive.com/view/empower...

📌@mdcurioni.bsky.social discusses the challenges of overcoming acquired resistance to #immunotherapy in #NSCLC, highlighting some positive and negative trial data from #ELCC26. Learn more in the #ESMODailyReporter 👉 https://ow.ly/f7WB50YA1b0

#ELCC26: Improved overall survival was observed with gotistobart, a novel anti-CTLA-4 antibody, versus docetaxel in stage 1 of the PRESERVE-003 trial in patients with squamous #NSCLC who progressed on anti-PD-(L)1 therapy.
#ESMODailyReporter 📌 https://ow.ly/TU2Z50YzKVC

The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 #ELCC26
WATCH HERE👉 vimeo.com/1160841460?s...
Presentation by Dr. Biagio Ricciuti🇺🇸 : Year in Review Early #NSCLC

Dizal's ZEGFROVY® Emerging as a Leader in Advanced NSCLC Treatment Dizal's clinical findings for ZEGFROVY® reveal promising antitumor efficacy as a front-line therapy against advanced NSCLC with uncommon mutations.

Dizal's ZEGFROVY® Emerging as a Leader in Advanced NSCLC Treatment #China #Shanghai #NSCLC #Dizal #ZEGFROVY®

New Insights from the Phase III MARIPOSA Trial on Amivantamab and Lazertinib Combination for NSCLC Patients The MARIPOSA trial reveals promising results for the combination therapy of Amivantamab and Lazertinib in Asian NSCLC patients, indicating improved survival rates compared to single-agent therapy.

New Insights from the Phase III MARIPOSA Trial on Amivantamab and Lazertinib Combination for NSCLC Patients #Japan #Tokyo #NSCLC #Lazertinib #Amivantamab

Improvement of Treatment Convenience in NSCLC with Librofaz® and Razkruz® Combination Therapy This article discusses the enhanced treatment convenience in non-small cell lung cancer using Librofaz® and Razkruz® combination therapy, highlighting clinical trial results.

Improvement of Treatment Convenience in NSCLC with Librofaz® and Razkruz® Combination Therapy #Japan #Tokyo #NSCLC #Librofaz #Razkruz

#ELCC26: Results from ETOP ADEPPT demonstrate the benefits of adagrasib in older patients but caution is needed in patients with poor performance status.
Read more of the latest insights in KRAS G12C-mutated #NSCLC in the #ESMODailyReporter ➡️ https://ow.ly/TXC050YzeZ0

The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 #ELCC26
Presentation by Dr. Gilberto Lopes🇺🇸 : Year in Review Early #NSCLC
WATCH NOW, NO REGISTRATION👉 buff.ly/hqSd5tp

Practice-changing research in 2025 in early NSCLC 🚀

ONCOassist Universal Link Opening ONCOassist app...

🔷 Fast Track status may support expedited development and regulatory review of TRI-611. This milestone reflects continued progress in expanding targeted therapy options for patients with ALK-driven tumors.

🔗 Read more: bit.ly/ONCOnews-26-...

#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC

COR2ED invites you to an upcoming virtual Experts Knowledge Share on the evolving TROP2-directed antibody drug conjugates (ADC) landscape in metastatic #NSCLC , & strategies to optimise the treatment experience. Monday, 11th May 2026, 11:30 EDT

REGISTER HERE 👉 engage.cor2ed.com/sign-up/lung...

Stephen V. Liu: Promising Results with Datopotamab Deruxtecan Combinations in NSCLC - OncoDaily Stephen V. Liu: Promising Results with Datopotamab Deruxtecan Combinations in NSCLC / Anthony Tolcher, Atsushi Horiike, Benjamin Levy, cancer, Chien-Chung

Promising Results with Datopotamab Deruxtecan Combinations in NSCLC - Stephen Liu

@stephenvliu.bsky.social @jtoonline.bsky.social

oncodaily.com/voices/steph...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC

Congratulations to Dr. Paola Nisticò, recipient of the SITC–Lunit Research Program. Her research will explore predictive factors in stage II–III NSCLC using Lunit SCOPE IO–derived immune features and multi-omic data to advance neoadjuvant chemo-immunotherapy. #NSCLC

Ahead of ELCC 2026, we spoke with expert lung cancer clinicians to gain their insights into the most anticipated abstracts that will be presented at the meeting.
🔒 Sign up here to read: www.onclive.com/view/thoraci...
#oncology #ELCC2026 #lungcancer #NSCLC #lcsm

New learning hub now live.

Explore expert-led insights on ALK+ NSCLC, including treatment strategies + AE management.

🔗 https://bit.ly/4spdBSu

#NSCLC #Oncology #CME

In the Beamion LUNG‑1 trial, zongertinib achieved a 76% response rate in untreated HER2‑mutant NSCLC, with many patients keeping responses beyond 6–12 months and tolerability described as manageable. #NSCLC #CancerNews #TCSC

The latest issue of @theinnovation.bsky.social features an article that reviews how novel pan-EGFR inhibitors can be designed to target all atypical EGFR mutations comprehensively.
doi.org/10.1016/j.xi...
#NSCLC #egfrinhibitor #drugdesign

No words to adequately describe how reading this made me feel.
I will agree that we're living in "the long middle" is maybe the most accurate. #NSCLC

Do you want to learn more about #BRAF?

Join us now at our Lung Cancer Targeted Therapies OncTalk!

#LungCancer #TargetedTherapies #V600E #NSCLC #GRACE #LungCancerInformation

Now presenting Dr. Christina Baik:

"KRAS and BRAF mutated NSCLC".

#TargetedTherapies #LungCancer #GRACE #KRAS #NSCLC #BRAF

Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment Dizal has unveiled significant Phase 3 results for ZEGFROVY, showcasing enhanced survival rates in lung cancer patients with EGFR mutations.

Dizal's Promising Phase 3 Study Results for ZEGFROVY in Lung Cancer Treatment #Shanghai #NSCLC #Dizal #ZEGFROVY

🚨 Coming Soon! 🚨

Prof. Nicolas Girard is joining us at #ELCC2026, to review the latest data on oncogene-addicted #NSCLC

Make sure you FOLLOW us to see his update! 🎬

🤝Endorsed by @lungcancereurope.bsky.social

Supported by an Independent Educational Grant from Bayer

#MedicalEducation #MedSky

Upcoming webinar: ‘The evolving TROP2-directed ADC landscape in metastatic #NSCLC: strategies to optimise the treatment experience’

🗓️11th May 26
🕜11:30 EDT/16:30 BST/17:30 CEST

Register engage.cor2ed.com/events/the-e...

Supported by an Independent Educational Grant from AstraZeneca. For HCPs only

The new guidance puts even greater emphasis on detailed molecular testing and PD‑L1 assessment so patients can receive the most appropriate first‑line treatment. Precision matters. #NSCLC #CancerCare #TCSC

🔜 #ELCC26 @myesmo.bsky.social
🔥T-cell engagers: A new class of drugs (ETOP IBCSG)
☑️ #SCLC #NSCLC #Metothelioma #Toxicities #CART
🎙️Chair: Dr. Luis Paz-Ares @solangepeters.bsky.social
@oncoalert.bsky.social LARVOL #LCSM